THERAPEUTICS
Treatment-resistant depression: adding low dose risperidone improves symptoms
| The first 150 words of the full text of this article appear below. |
Ramy A Mahmoud
Correspondence to: Ramy A Mahmoud, ETHICON, Inc, PO Box 151, US Highway 22 West, Room E314, Somerville, NJ 08876, USA; rmahmou@ethus.jnj.com
How effective is augmentation with low-dose risperidone for treatment-resistant depression in adults?
274 outpatients aged 18–65 years with DSM-IV major depressive disorder who did not respond to standard antidepressant monotherapy during 4 weeks treatment prior to randomisation (non-response defined as Clinical Global Impression-Severity of Illness (CGI-S) score
4 and Carroll Depression Scale score
20). Exclusions: pregnancy; substance or alcohol use disorder; current use of tricyclic antidepressant, monoamine oxidase inhibitor, antiepileptic, or mood stabiliser; suicidal risk; serious medical or neurological illness; treatment for attention deficit/hyperactivity disorder or narcolepsy.
Outpatient clinics in public and private care settings and psychiatric centres in the USA; recruitment October 2004 to November 2005.
Six weeks treatment augmentation with low-dose risperidone (0.25 mg for the first 3 days, 0.5 mg on days 4–15,
LSU Health Sciences Center, New Orleans, LA, USA
Register for free content
The full back archive is now available for all BMJ Journals. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006 right back to volume 1 issue 1. Register here to access the free archive of all BMJ Journals.
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
